{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:27:16Z","timestamp":1785770836582,"version":"3.56.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA035813"],"award-info":[{"award-number":["R01DA035813"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Rationale<\/jats:title>\n<jats:p>Cognitive benefits of nicotinic acetylcholine receptor (nAChR) agonists are well established but have generally been of small magnitude and uncertain clinical significance. A way of raising the effect size may be to facilitate agonist-induced responses by co-administering a nAChR positive allosteric modulator (PAM).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>The aim was to test whether galantamine, a PAM at several nAChR subtypes, can potentiate the cognitive-enhancing effects of nicotine.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Twenty-six adult never-smokers were treated, in a double-blind counterbalanced sequence, with nicotine (7\u00a0mg\/24\u00a0h, transdermally) and galantamine (4\u00a0mg, p.o.) combined, nicotine alone, galantamine alone, and double placebo. A low dose of galantamine was chosen to minimize acetylcholinesterase inhibition, which was verified in blood assays. In each condition, participants were tested with three cognitive tasks.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Nicotine significantly improved reaction time (RT) and signal detection in a visuospatial attention task and the Rapid Visual Information Processing Task. Galantamine did not modulate these effects. A trend toward RT reduction by galantamine correlated with acetylcholinesterase inhibition. In a change detection task, there were no effects of nicotine or galantamine alone on accuracy or RT. However, both drugs combined acted synergistically to reduce RT. This effect was not associated with acetylcholinesterase inhibition.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A pattern consistent with allosteric potentiation of nicotine effects by galantamine was observed on one of six performance measures. This may reflect specific nAChR subtype involvement, or additional pharmacological actions of galantamine may have overshadowed similar interactions on other measures. The finding suggests that allosteric potentiation of nAChR agonist-induced cognitive benefits is possible in principle.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00213-019-05363-4","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T08:03:08Z","timestamp":1572854588000},"page":"219-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects"],"prefix":"10.1007","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0709-4543","authenticated-orcid":false,"given":"Britta","family":"Hahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Shrieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory K.","family":"Olmstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie B.","family":"Yuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Chiappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna F. R.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edson X.","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Fawcett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"5363_CR1","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.2741\/2424","volume":"12","author":"CE Adams","year":"2007","unstructured":"Adams CE, Stevens KE (2007) Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Front Biosci 12:4755\u20134772","journal-title":"Front Biosci"},{"key":"5363_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","volume":"89","author":"EX Albuquerque","year":"2009","unstructured":"Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73\u2013120","journal-title":"Physiol Rev"},{"key":"5363_CR3","doi-asserted-by":"crossref","unstructured":"Choueiry J, Blais CM, Shah D, Smith D, Fisher D, Labelle A, Knott V (2019) Combining CDP-choline and galantamine, an optimized alpha7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia. Int J Psychophysiol","DOI":"10.1016\/j.ijpsycho.2019.02.005"},{"key":"5363_CR4","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale","edition":"2"},{"key":"5363_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.20982\/tqmp.01.1.p042","volume":"1","author":"D Cousineau","year":"2007","unstructured":"Cousineau D (2007) Confidence intervals in within-subject designs: a simpler solution to Loftus and Masson\u2019s method. Tutor Quant Methods Psychol 1:42\u201345","journal-title":"Tutor Quant Methods Psychol"},{"key":"5363_CR6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3233\/JAD-2007-11411","volume":"11","author":"JT Coyle","year":"2007","unstructured":"Coyle JT, Geerts H, Sorra K, Amatniek J (2007) Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer\u2019s neuropathology. J Alzheimers Dis 11:491\u2013507","journal-title":"J Alzheimers Dis"},{"key":"5363_CR7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1124\/mol.64.5.1217","volume":"64","author":"FA Dajas-Bailador","year":"2003","unstructured":"Dajas-Bailador FA, Heimala K, Wonnacott S (2003) The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol 64:1217\u20131226","journal-title":"Mol Pharmacol"},{"key":"5363_CR8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2013.05.023","volume":"148","author":"SI Deutsch","year":"2013","unstructured":"Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM (2013) Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy. Schizophr Res 148:138\u2013144","journal-title":"Schizophr Res"},{"key":"5363_CR9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0091-3057(00)00399-3","volume":"67","author":"RV Fant","year":"2000","unstructured":"Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP (2000) A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 67:479\u2013482","journal-title":"Pharmacol Biochem Behav"},{"key":"5363_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02805972","volume":"127","author":"J Foulds","year":"1996","unstructured":"Foulds J, Stapleton J, Swettenham J, Bell N, McSorley K, Russell MA (1996) Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology 127:31\u201338","journal-title":"Psychopharmacology"},{"key":"5363_CR11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/j.1552-4604.1993.tb03938.x","volume":"33","author":"J Gorsline","year":"1993","unstructured":"Gorsline J, Gupta SK, Dye D, Rolf CN (1993) Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm (Nicotine Transdermal System). J Clin Pharmacol 33:161\u2013168","journal-title":"J Clin Pharmacol"},{"key":"5363_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bcp.2009.05.024","volume":"78","author":"C Gotti","year":"2009","unstructured":"Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, Moretti M, Pedrazzi P, Pucci L, Zoli M (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 78:703\u2013711","journal-title":"Biochem Pharmacol"},{"key":"5363_CR13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1037\/h0031246","volume":"75","author":"JB Grier","year":"1971","unstructured":"Grier JB (1971) Nonparametric indexes for sensitivity and bias: computing formulas. Psychol Bull 75:424\u2013429","journal-title":"Psychol Bull"},{"key":"5363_CR14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/mol.107.035410","volume":"72","author":"JH Gronlien","year":"2007","unstructured":"Gronlien JH, Hakerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, Malysz J (2007) Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 72:715\u2013724","journal-title":"Mol Pharmacol"},{"key":"5363_CR15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/sj.npp.1300102","volume":"28","author":"AJ Grottick","year":"2003","unstructured":"Grottick AJ, Haman M, Wyler R, Higgins GA (2003) Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology 28:880\u2013887","journal-title":"Neuropsychopharmacology"},{"key":"5363_CR16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1993.tb04221.x","volume":"36","author":"SK Gupta","year":"1993","unstructured":"Gupta SK, Benowitz NL, Jacob P 3rd, Rolf CN, Gorsline J (1993) Bioavailability and absorption kinetics of nicotine following application of a transdermal system. Br J Clin Pharmacol 36:221\u2013227","journal-title":"Br J Clin Pharmacol"},{"key":"5363_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-13665-3_5","volume":"23","author":"B Hahn","year":"2015","unstructured":"Hahn B (2015) Nicotinic receptors and attention. Curr Top Behav Neurosci 23:103\u2013135","journal-title":"Curr Top Behav Neurosci"},{"key":"5363_CR18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.biopsych.2013.03.017","volume":"74","author":"B Hahn","year":"2013","unstructured":"Hahn B, Harvey AN, Concheiro-Guisan M, Huestis MA, Holcomb HH, Gold JM (2013) A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry 74:436\u2013443","journal-title":"Biol Psychiatry"},{"key":"5363_CR19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.neuroimage.2006.04.177","volume":"32","author":"B Hahn","year":"2006","unstructured":"Hahn B, Ross TJ, Stein EA (2006) Neuroanatomical dissociation between bottom-up and top-down processes of visuospatial selective attention. Neuroimage 32:842\u2013853","journal-title":"Neuroimage"},{"key":"5363_CR20","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1523\/JNEUROSCI.5129-06.2007","volume":"27","author":"B Hahn","year":"2007","unstructured":"Hahn B, Ross TJ, Yang Y, Kim I, Huestis MA, Stein EA (2007) Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci 27:3477\u20133489","journal-title":"J Neurosci"},{"key":"5363_CR21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00213-011-2258-8","volume":"217","author":"B Hahn","year":"2011","unstructured":"Hahn B, Shoaib M, Stolerman IP (2011) Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement. Psychopharmacology 217:75\u201382","journal-title":"Psychopharmacology"},{"key":"5363_CR22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156802610790410983","volume":"10","author":"SN Haydar","year":"2010","unstructured":"Haydar SN, Dunlop J (2010) Neuronal nicotinic acetylcholine receptors\u2014targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer\u2019s disease. Curr Top Med Chem 10:144\u2013152","journal-title":"Curr Top Med Chem"},{"key":"5363_CR23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-010-1848-1","volume":"210","author":"SJ Heishman","year":"2010","unstructured":"Heishman SJ, Kleykamp BA, Singleton EG (2010) Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 210:453\u2013469","journal-title":"Psychopharmacology"},{"key":"5363_CR24","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1601-183X.2011.00689.x","volume":"10","author":"LE Hong","year":"2011","unstructured":"Hong LE, Yang X, Wonodi I, Hodgkinson CA, Goldman D, Stine OC, Stein ES, Thaker GK (2011) A CHRNA5 allele related to nicotine addiction and schizophrenia. Genes Brain Behav 10:530\u2013535","journal-title":"Genes Brain Behav"},{"key":"5363_CR25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/npp.2010.9","volume":"35","author":"WM Howe","year":"2010","unstructured":"Howe WM, Ji J, Parikh V, Williams S, Mocaer E, Trocme-Thibierge C, Sarter M (2010) Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 35:1391\u20131401","journal-title":"Neuropsychopharmacology"},{"key":"5363_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2012.08.012","volume":"137","author":"R Hurst","year":"2013","unstructured":"Hurst R, Rollema H, Bertrand D (2013) Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 137:22\u201354","journal-title":"Pharmacol Ther"},{"key":"5363_CR27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00259-010-1644-5","volume":"38","author":"K Kendziorra","year":"2011","unstructured":"Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, Luthardt J, Schildan A, Patt M, Sorger D, Seese A, Gertz HJ, Sabri O (2011) Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer\u2019s disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 38:515\u2013525","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5363_CR28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0306-4522(01)00538-3","volume":"109","author":"ED Levin","year":"2002","unstructured":"Levin ED, Bradley A, Addy N, Sigurani N (2002) Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 109:757\u2013765","journal-title":"Neuroscience"},{"key":"5363_CR29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/1568007023339102","volume":"1","author":"ED Levin","year":"2002","unstructured":"Levin ED, Rezvani AH (2002) Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 1:423\u2013431","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"5363_CR30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/36846","volume":"390","author":"SJ Luck","year":"1997","unstructured":"Luck SJ, Vogel EK (1997) The capacity of visual working memory for features and conjunctions. Nature 390:279\u2013281","journal-title":"Nature"},{"key":"5363_CR31","volume-title":"Profile of mood states manual","author":"DM McNair","year":"1971","unstructured":"McNair DM, Lorr M, Droppleman LF (1971) Profile of mood states manual. Educational and Industrial Testing Service, San Diega"},{"key":"5363_CR32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.physbeh.2014.09.010","volume":"138","author":"KC Morasch","year":"2015","unstructured":"Morasch KC, Aaron CL, Moon JE, Gordon RK (2015) Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults. Physiol Behav 138:165\u2013172","journal-title":"Physiol Behav"},{"key":"5363_CR33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.20982\/tqmp.04.2.p061","volume":"4","author":"RD Morey","year":"2008","unstructured":"Morey RD (2008) Confidence intervals from normalized data: a correction of Cousineau. Tutor Quant Methods Psychol 4:61\u201364","journal-title":"Tutor Quant Methods Psychol"},{"key":"5363_CR34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coph.2003.11.001","volume":"4","author":"PA Newhouse","year":"2004","unstructured":"Newhouse PA, Potter A, Singh A (2004) Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4:36\u201346","journal-title":"Curr Opin Pharmacol"},{"key":"5363_CR35","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bcp.2011.06.008","volume":"82","author":"PA Newhouse","year":"2011","unstructured":"Newhouse PA, Potter AS, Dumas JA, Thiel CM (2011) Functional brain imaging of nicotinic effects on higher cognitive processes. Biochem Pharmacol 82:943\u2013951","journal-title":"Biochem Pharmacol"},{"key":"5363_CR36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(00)00064-9","volume":"393","author":"E Perry","year":"2000","unstructured":"Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393:215\u2013222","journal-title":"Eur J Pharmacol"},{"key":"5363_CR37","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/npp.2010.12","volume":"35","author":"N Petrovsky","year":"2010","unstructured":"Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mossner R, Collier DA, Kuhn KU, Maier W, Wagner M, Kumari V (2010) Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology 35:1429\u20131439","journal-title":"Neuropsychopharmacology"},{"key":"5363_CR38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/138161210790170166","volume":"16","author":"RJ Radek","year":"2010","unstructured":"Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG (2010) Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des 16:309\u2013322","journal-title":"Curr Pharm Des"},{"key":"5363_CR39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neulet.2010.01.022","volume":"471","author":"SL Rushforth","year":"2010","unstructured":"Rushforth SL, Allison C, Wonnacott S, Shoaib M (2010) Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: a novel use of the odour span task. Neurosci Lett 471:114\u2013118","journal-title":"Neurosci Lett"},{"key":"5363_CR40","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","volume":"305","author":"M Samochocki","year":"2003","unstructured":"Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024\u20131036","journal-title":"J Pharmacol Exp Ther"},{"key":"5363_CR41","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/mol.61.5.1222","volume":"61","author":"MD Santos","year":"2002","unstructured":"Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222\u20131234","journal-title":"Mol Pharmacol"},{"key":"5363_CR42","first-page":"1096","volume":"7","author":"A Singh","year":"2004","unstructured":"Singh A, Potter A, Newhouse P (2004) Nicotinic acetylcholine receptor system and neuropsychiatric disorders. IDrugs 7:1096\u20131103","journal-title":"IDrugs"},{"key":"5363_CR43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00213-012-2763-4","volume":"224","author":"M Sofuoglu","year":"2012","unstructured":"Sofuoglu M, Herman AI, Li Y, Waters AJ (2012) Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharmacology 224:413\u2013420","journal-title":"Psychopharmacology"},{"key":"5363_CR44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/med.2610150105","volume":"15","author":"IP Stolerman","year":"1995","unstructured":"Stolerman IP, Mirza NR, Shoaib M (1995) Nicotine psychopharmacology: addiction, cognition and neuroadaptation. Med Res Rev 15:47\u201372","journal-title":"Med Res Rev"},{"key":"5363_CR45","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/13543784.16.12.1987","volume":"16","author":"M Villarroya","year":"2007","unstructured":"Villarroya M, Garcia AG, Marco-Contelles J, Lopez MG (2007) An update on the pharmacology of galantamine. Expert Opin Investig Drugs 16:1987\u20131998","journal-title":"Expert Opin Investig Drugs"},{"key":"5363_CR46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2011.03.022","volume":"99","author":"TL Wallace","year":"2011","unstructured":"Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG (2011) Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 99:130\u2013145","journal-title":"Pharmacol Biochem Behav"},{"key":"5363_CR47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s002130050514","volume":"135","author":"DM Warburton","year":"1998","unstructured":"Warburton DM, Mancuso G (1998) Evaluation of the information processing and mood effects of a transdermal nicotine patch. Psychopharmacology 135:305\u2013310","journal-title":"Psychopharmacology"},{"key":"5363_CR48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00427761","volume":"82","author":"K Wesnes","year":"1984","unstructured":"Wesnes K, Warburton DM (1984) Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82:147\u2013150","journal-title":"Psychopharmacology"},{"key":"5363_CR49","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bcp.2011.05.001","volume":"82","author":"DK Williams","year":"2011","unstructured":"Williams DK, Wang J, Papke RL (2011) Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol 82:915\u2013930","journal-title":"Biochem Pharmacol"},{"key":"5363_CR50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2011.06261.x","volume":"1248","author":"VC Wing","year":"2012","unstructured":"Wing VC, Wass CE, Soh DW, George TP (2012) A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann N Y Acad Sci 1248:89\u2013106","journal-title":"Ann N Y Acad Sci"},{"key":"5363_CR51","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/0091270002042009007","volume":"42","author":"Q Zhao","year":"2002","unstructured":"Zhao Q, Brett M, Van Osselaer N, Huang F, Raoult A, Van Peer A, Verhaeghe T, Hust R (2002) Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J Clin Pharmacol 42:1002\u20131010","journal-title":"J Clin Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05363-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-019-05363-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05363-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:20:13Z","timestamp":1604362813000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-019-05363-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5363"],"URL":"https:\/\/doi.org\/10.1007\/s00213-019-05363-4","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Participants were recruited from the local community through internet advertising, flyers, and referrals, and gave written informed consent for a protocol approved by the University of Maryland Baltimore Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}